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Inappropriate use of antibiotic drugs in humans and animals has led to widespread resistance among microbial pathogens.
Resistance is the phenotypic expression corresponding to genetic changes caused by either mutation or acquisition of new genetic
information. In some cases, multidrug resistance occurs. Streptococcus pneumoniae is one of the most important respiratory
pathogens, playing a major role in both upper and lower respiratory tract infections. Pneumococcal resistance to antimicrobials
may be acquired by means of horizontal transfer followed by homologous recombination of genetic material from the normal
flora of the human oral cavity or by means of mutation. Resistance to penicillins and macrolides has been increasing for some
time, but, recently, fluoroquinolone resistance has become an issue as well. We are concerned that, if fluoroquinolones are
approved for use in children, their widespread use will result in rapid emergence of pneumococcal resistance, because children
are more often colonized in the nasopharynx with high-density populations of pneumococci than are adults.
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DISCOVERY OF ANTIBIOTICS
AND EMERGENCE
OF MICROBIAL RESISTANCE
The development of antimicrobials is con-
sidered among the most important med-
ical advances of the twentieth century [1].
However, penicillin G had barely been re-
leased when reports of penicillinase-pro-
ducing isolates of Staphylococcus aureus
appeared, raising a note of caution [2]. We
believe it is important to review the history
and biology of antibiotic resistance, to
comment on contemporary issues relating
to emerging resistance, and, most impor-
tantly, to argue against the unnecessary use
of fluoroquinolones to treat children, a
development that may exacerbate this
phenomenon.
Antimicrobial agents are used exten-
sively around the world, and many drugs,
including fluoroquinolones, are used for
growth promotion and prophylaxis in an-
imal husbandry. Unfortunately, there is a
correlation between the total amount of
drug use and the appearance and dissem-
ination of resistant microbial strains [3].
Societal expectations, coupled with phy-
sicians’ intrinsic desire to help patients,
have contributed to widespread abuse of
antibiotics. A recent survey highlighted
this, showing that, although only 22%
of patients seeking medical care had
an infection diagnosed, 67% were given
antibiotics as a result of their physician
visit [4].
Bacteria have developed ingenious
strategies to protect themselves against an-
timicrobials, which they themselves often
produce. For example, aminoglycoside-in-
activating enzymes are produced by strains
of Streptomyces that also produce an ami-
noglycoside [5], and the van gene cluster
that codes for high-level vancomycin re-
sistance recently has been found in the
glycopeptide-producing microorganisms
[6] as well as in a bacterium that is present
in a widely distributed biopesticide [7]. It
is postulated that resistance genes escaped
from soil microorganisms and, after pas-
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sage and remodeling in other bacteria, en-
tered human pathogens [8]. Bacterial iso-
lates displaying resistance to tetracycline
and streptomycin have been isolated from
stool samples obtained from Solomon Is-
landers who have never been exposed to
antibiotics [9]. These are but a few ex-
amples in which microbes that have not
been exposed to antibiotics have been
found to have the genetic machinery to
resist antimicrobial agents.
The phenotypic expression of resistance
corresponds to genetic alterations that re-
sult either from horizontal acquisition of
genetic information from other organisms
or from adaptive mutations in the micro-
bial genome. Compounding the problem
of emerging resistance is the appearance,
relatively recently, of organisms with mul-
tidrug resistance. This occurs when the or-
ganisms acquire resistance genes carried
by plasmids or transposons. In certain
bacteria, such as Streptococcus pneumon-
iae, resistance may even be acquired by
direct incorporation and remodeling of
DNA from closely related oral commensal
bacteria, by the process of natural trans-
formation [10]. It is only recently that we
have begun to appreciate the complexity
of the mechanisms in which the “normal”
human flora develops resistance; when
humans are treated unnecessarily or
treated with inappropriate regimens, in-
vading pathogens can acquire resistance-
coding DNA from colonizing microflora
[11]. Although both clinical practice and
environmental conditions may help to en-
hance the growth of select bacteria with
newly acquired resistance genes, it is clear
that the selection pressure generated by the
use of antibiotics is one of the critical fac-
tors in the emergence and dissemination
of bacteria resistant to antimicrobial
agents [3, 12, 13].
DRUG DEVELOPMENT
AND EMERGENCE OF
ANTIMICROBIAL RESISTANCE
Bacteria can manifest resistance by a va-
riety of mechanisms. For the penicillin-
resistant pneumococcus, however, the
only significant mechanism demonstrated
to date is alteration in the penicillin-bind-
ing proteins (PBPs), the target site for b-
lactams. This alteration is accomplished by
remodeling of DNA through the unique
mechanism of natural transformation
[14]. The PBPs themselves are transpep-
tidase and carboxypeptidase enzymes in-
volved in bacterial cell wall synthesis and
are the primary target sites for all b-lac-
tams. It is not surprising, therefore, that
penicillin-resistant pneumococci also ex-
hibit varying degrees of resistance to other
penicillins and, occasionally, to cephalo-
sporins. The situation is further compli-
cated by the fact that certain strains
are resistant to third-generation cepha-
losporins but susceptible to penicillin G
[15, 16].
Analysis of the sequence of the struc-
tural genes for PBPs indicated that, al-
though the genes of susceptible S. pneu-
moniae are conserved, those of resistant
strains have a mosaic structure composed
of blocks, some of which are similar to
and some of which are different from their
counterparts in susceptible strains [17].
The “diverged regions” are acquired from
other bacterial species that are part of the
normal flora of the human oral cavity,
such as Streptococcus mitis or Streptococcus
oralis (viridans group streptococci), by
means of horizontal transfer (transfor-
mation) followed by homologous recom-
bination of genetic material [14, 18].
“Multidrug resistance” refers to resis-
tance to 3 antimicrobials that have dif-
ferent mechanisms of action. This resis-
tance is due to the stable coexistence in
the bacterial genome of mutations in var-
ious housekeeping genes or of assortments
of acquired foreign genes, each of which
confers resistance to a class of antibiotics
[19]. Multidrug-resistant S. pneumoniae,
first reported in South Africa in 1977, have
now been recovered in a number of coun-
tries [20–22]. One type of resistance of
particular concern to clinicians is that me-
diated by the ermB gene. This confers re-
sistance not only to the macrolide class
but to lincosamides and streptogramin B
compounds as well [23, 24]. For unknown
reasons, some multidrug-resistant S. pneu-
moniae clones have disseminated world-
wide and account for the observed coresis-
tance to various drug classes [25].
Recently there has been a marked in-
crease in the percentages of pneumococcal
isolates that are penicillin resistant. Most
worrisome is the propensity for pneu-
mococcal resistance to penicillin G to be
associated with reduced susceptibility to
other drugs, such as macrolides, lincos-
amides, and streptogramins; tetracyclines;
chloramphenicol; and trimethoprim-sul-
famethoxazole. In the United States,
58.9% of pneumococcal isolates recovered
from blood that are penicillin resistant are
also macrolide resistant (D. Sahm, per-
sonal communication). Fluoroquinolone
resistance in pneumococci has also been
reported recently [26], and an association
between penicillin and fluoroquinolone
resistance in the pneumococcus has been
suggested [27, 28].
Fluoroquinolone resistance is not lim-
ited to S. pneumoniae and has been doc-
umented in other pathogens as well, in-
cluding those responsible for urinary,
respiratory, and gastrointestinal tract in-
fections, skin and soft-tissue and bone and
joint infections, sexually transmitted dis-
eases, and ulcers. The microorganisms
include gram-positive and gram-negative
cocci, such as methicillin-susceptible and
methicillin-resistant S. aureus and Neis-
seria gonorrhoeae, respectively; gram-neg-
ative rods, such as Pseudomonas aerugino-
sa and Serratia marcescens; Mycobacterium
tuberculosis and atypical mycobacteria;
and Campylobacter jejuni and Helicobacter
pylori [29–36].
The critical question, however, is
whether in vitro resistance necessarily
means that treatment will result in clinical
failure. This question is important, be-
cause S. pneumoniae causes infection in a
number of sites that are not only anatom-
ically distinct but functionally and biolog-
ically distinct as well. Otitis media is, es-
sentially, a closed-space infection, and
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meningitis treatment is complicated by the
presence of the blood-brain barrier.
For penicillin therapy of pneumococ-
cal pneumonia, no bacteriologically con-
firmed treatment failures have been re-
ported for infections caused by organisms
with penicillin MICs of !4 mg/L [37–39].
For strains with MICs of 4 mg/L, data
are conflicting regarding the occurrence of
treatment failure [40–45].
There are also data regarding the rele-
vance of macrolide-resistant S. pneumon-
iae. A recent paper described 4 patients
with infection caused by S. pneumoniae
with low-level macrolide resistance who
failed to respond to outpatient oral ther-
apy with either azithromycin or clarith-
romycin [46]. Pharmacodynamic prin-
ciples suggest that macrolide-resistant
strains with MICs of8 mg/L should not
respond to macrolide therapy, and 120
cases have now been documented of
pneumococcal bacteremia due to such
macrolide-resistant strains that occurred
after macrolide therapy [46–50].
In vitro evidence suggests that fluoro-
quinolones, such as moxifloxacin and tro-
vafloxacin, are superior to older agents,
such as ciprofloxacin and levofloxacin, in
that they do not permit subpopulations of
bacteria with single mutations to survive
after exposure to drug concentrations that
exceed their MICs and are, thus, less likely
to select for resistant mutants [51]. Clin-
ical data also support this observation: for
example, gatifloxacin was compared with
levofloxacin in a prospective, blinded trial,
and the only culture-proven treatment
failures for cases of pneumonia caused
by S. pneumoniae (3 cases) or S. aureus
(2 cases) occurred in the levofloxacin
arm [52].
It would appear, therefore, that the
problem of fluoroquinolone resistance is
solved and that 2 new fluoroquinolones,
moxifloxacin and gatifloxacin, that have
potent antipneumococcal activity are now
available for use. Unfortunately, the prob-
lem is far from solved. A disturbing article
reported that 2 of 29 pneumococcal iso-
lates were resistant not only to ciproflox-
acin but to moxifloxacin and trovafloxacin
as well—2 of the very potent “newer
quinolones” that were under development
and had not seen widespread clinical use
at the time of publication [53]. Further-
more, a case-control study from Hong
Kong demonstrated that a key risk factor
for acquisition of fluoroquinolone-resis-
tant S. pneumoniae was prior treatment
with ofloxacin, levofloxacin, or ciproflox-
acin (OR, 10.7) [54]. These findings
clearly raise concerns that use of earlier
fluoroquinolones poses the risk of infec-
tion with organisms with resistance to
newer, more potent agents. The study
showed that pneumococcal resistance to
fluoroquinolones is essentially a class ef-
fect [54], and, by extrapolation from past
experience, it seems clear that overuse of
one member of this class may weaken the
effectiveness of structurally related drugs.
ADVERSE DRUG REACTIONS
A detailed discussion of adverse drug re-
actions is beyond the scope of this article.
However, discussion of fluoroquinolones
would be incomplete without some men-
tion of drug-related toxicity. As a result of
initial concerns about potential toxicity in
children, there are few data on the exper-
imental use of these agents in pediatric
practice, and most of our information de-
rives from animal experiments, experi-
mental and clinical use to treat adults, and
use to treat children as part of compas-
sionate-use programs.
The description of cartilage lesions in
weight-bearing diarthrodial joints of ju-
venile animals that occurred following ex-
posure to fluoroquinolones led to the
moratorium on the use of fluoroquino-
lones to treat children. Arthropathy is a
class effect, and virtually all fluoroquino-
lones tested have induced changes in im-
mature cartilage in all animals studied
[55–57]. The lesions typically are fissures,
blisters, and erosions resulting from ne-
crosis of the chondrocytes and disruption
of the extracellular matrix [55]. The pre-
cise mechanism is unknown, and no def-
inite relationship has been established be-
tween fluoroquinolone structure and this
adverse event. It is thought, however, that
the fluoroquinolones chelate magnesium
ions, resulting in disruption of the signal
transduction from the chondrocyte sur-
face integrin receptors that are thought to
play a role in maintaining the integrity of
the cartilage matrix [58]. To date, there is
no evidence categorically linking fluo-
roquinolone use to arthropathy in hu-
mans, and the long-standing restrictions
on fluoroquinolone use appear to be lift-
ing [59].
Other adverse reactions that occur in
adults also will be of potential concern in
children, if these drugs are released for
general use. They are seizures; cardiotox-
icity, in the form of QT interval prolon-
gation and malignant arrhythmias; and
phototoxicity. CNS effects, which rarely
include seizures, occur either as the result
of direct action of a drug on CNS recep-
tors or as the result of an interaction be-
tween the fluoroquinolone and another
pharmacologic agent. Direct actions are
further divided into the blocking of the
g-aminobutyric acid receptor and primary
excitatory effects mediated by the N-
methyl-d-aspartate adenosine receptor
[60, 61].
The main area of interest related to car-
diotoxicity is prolongation of the QT in-
terval [62]. This phenomenon has been
well described with other agents, including
the macrolides, and it may be a class effect
for the fluoroquinolones. The precise
mechanism is not known, but it is likely
multifactorial. It is generally thought that
fluoroquinolones should not be given to
patients known to have QT interval pro-
longation nor to patients receiving con-
comitant therapy with agents that might
increase the QT interval and induce
bradycardia or torsades de pointes.
Phototoxicity may occur if the dose of
a photolabile drug and exposure to UV
light are sufficiently high. Certain fluoro-
quinolones can cause the formation of
toxic monovalent oxygen radicals after
such exposure, and these, in turn, may
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attack cellular lipid membranes, resulting,
ultimately, in the clinical manifestations of
phototoxicity [63]. Halogenation at the C-
8 position is one of the main determinants
of such an adverse event [64].
CURRENT DILEMMA
AND FUTURE PROBLEMS
Evidence is accumulating that multidrug
resistance in pneumococci is related to
prescription of antimicrobial agents to a
critically important reservoir for these or-
ganisms: children. This likely occurs be-
cause children, more often than adults, are
colonized with high-density populations
of pneumococci in the nasopharynx,
which increases the potential for resistance
development and, thus, raises the specter
of rapidly accelerating development of re-
sistance to antimicrobial drugs, including
fluoroquinolones, should this class of an-
timicrobials be overused among children,
as they have been among adults. Sup-
porting this concern are studies of day care
and pediatric chronic care centers that
have found a very high prevalence of na-
sopharyngeal carriage of drug-resistant
strains of S. pneumoniae [65, 66]. Over-
crowding facilitates the transmission of re-
sistant strains from colonized to suscep-
tible infants and children who, in turn,
serve as a source for further transmission
to family members and, ultimately, to the
general population [67]. Investigators also
found high rates of pneumococcal carriage
(50%) among children [68] and found
that prior receipt of antibiotics signifi-
cantly increased the risk of harboring a
drug-resistant strain [68, 69]. However,
rather than suggesting that new antimi-
crobials were needed for the treatment of
children, the authors of the study rec-
ommended reducing unnecessary use of
antimicrobials in the community as the
most appropriate course of action, partic-
ularly because most of the infections
treated with antimicrobials are viral [69].
Finally, the prevalence of macrolide resis-
tance among pneumococci doubled in the
United States between 1995 and 1999,
during which time use of macrolides re-
mained stable in the population5 years
of age but increased by 320% in the pop-
ulation !5 years of age [70].
A new concern about widespread use
of fluoroquinolones to treat children, as
well as adults, is the recent recognition
of horizontal transfer of fluoroquinolone
resistance from viridans group strepto-
cocci (such as S. oralis and S. mitis) to
S. pneumoniae [10, 11]. Once resistance
mutations develop in these naturally com-
mensal organisms as a result of fluoro-
quinolone exposure (even in the absence
of pathogenic pneumococci), any subse-
quent pneumococcal infection carries the
risk that the infecting strain of S. pneu-
moniae will readily acquire fluoroquino-
lone resistance–determining DNA regions
when antimicrobial therapy is instituted.
These fluoroquinolone-resistant S. pneu-
moniae can then be easily spread from
child to parent, followed by widespread
dissemination to the adult population.
The dangerous triad of antibiotic mis-
use, a reservoir of resistance genes, and a
closed-space pneumococcal infection (oti-
tis media) would come together if fluoro-
quinolones were approved for general use
in the pediatric population. The odds of
the appearance and dissemination of re-
sistant strains through the emergence of
de novo resistance and clonal spread
would likely increase dramatically. Fluoro-
quinolone resistance has already been ob-
served in globally distributed clones of
multidrug-resistant pneumococci [71].
These clones are encapsulated and belong
to the serotypes most commonly found
among children. Resistant isolates already
exist and, under the influence of enhanced
selection pressure, will rapidly disseminate
themselves or their resistance genes. Our
previous experience with the spread of
penicillin resistance allows us to predict
that such spread will occur with other
drug classes. It is likely that, shortly after
their approval for use in pediatric practice,
fluoroquinolones will be as widely used as
they are in the adult population, and any
advantages of using them will dissipate
quickly. As already mentioned, pneumo-
cocci have cross-resistance, albeit at vari-
ous levels, to fluoroquinolones. For strains
that are more resistant to the less active
drugs [19], the most active agents will
likely select for clones that are resistant to
both the older and newer drugs. Thus,
inappropriate and unnecessary use of the
new fluoroquinolones will exert the selec-
tion pressure required for clonal dissem-
ination of the most-resistant isolates.
This brings us to the heart of the matter.
Do we really need fluoroquinolones for
general use in pediatric practice? The
broad spectrum of many of the fluoro-
quinolones, coupled with their ease of use
(once-daily dosing for many patients),
makes them appealing to physicians and
patients alike. There is no question that
fluoroquinolones are valuable for treat-
ment of selected pediatric patients. How-
ever, we propose that their use to treat
children be limited to those specific in-
fections complicated by special conditions
for which the benefit of these drugs is clear
and for which no alternative safe and ef-
fective antibiotic therapy is available [72,
73]. To date, potential pediatric indica-
tions for fluoroquinolones include pseu-
domonal bronchopulmonary exacerba-
tion in cystic fibrosis [74–76], complicated
urinary tract infection [77, 78], invasive
gastrointestinal infection [79, 80], and
chronic ear infection [81]. For these 4 spe-
cific infections, results of controlled clin-
ical trials have shown similar efficacy for
the fluoroquinolones and conventional
regimens [74–81]. Preliminary experience
with pediatric patients also indicates that
the fluoroquinolones are effective and safe
for the eradication of nasopharyngeal car-
riage of meningococci [82] and for treat-
ment of selected patients with febrile neu-
tropenia [80, 83, 84] or invasive infection
caused by multidrug-resistant pathogens
[85, 86]. Such limited use certainly does
not require that the regulatory authorities
approve fluoroquinolones for general use
in the pediatric population.
The selection of antibiotic-resistant
pneumococci, however, is likely to occur
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more rapidly among children than among
adults, because nasopharyngeal coloniza-
tion with high-density populations of
pneumococci is more common among
children [87]. Fluoroquinolones have not
been widely prescribed for children be-
cause of potential toxicity problems; there-
fore, there are no data on the effect of such
drugs on the selection of resistant pneu-
mococcal mutants in the nasopharynx of
children, whereas there are such data for
adults [88]. Thus, although this class of
drugs is able to eradicate meningococcal
carriage in children, it would be prudent
to conduct studies of selection for resistant
mutants, as a matter of urgency, before
use of the new fluoroquinolones to treat
children is considered.
There is no compelling need to extend
regulatory approval for use of these im-
portant agents in persons aged !16 years.
Pichichero et al. [89] recently documented
that 175% of pediatric patients who vis-
ited a physician for acute respiratory tract
infection did not require antimicrobial
therapy at the first office visit. The ideal
was to prescribe antimicrobials only for
those patients who clearly needed them.
It is of interest that there were more return
visits related to the initial infection among
children who were given antibiotics than
among children who were not [89]. The
authors of this commentary are unani-
mous in their desire for more prudent use
of fluoroquinolones to treat adult patients
and in their objection to the approval of
fluoroquinolones for use in pediatric pa-
tients and the subsequent widespread use
of these drugs [89]. Hooper [90] raised a
similar note of caution in his recent review
of the fluoroquinolones. He suggests that
avoidance of their routine administration
may play a significant role in limiting
the spread of pneumococcal resistance to
these drugs.
Multiple alternatives are usually avail-
able for treatment of most infections in
the pediatric population. Reserving the
fluoroquinolones for treatment of adults,
in whom their efficacy and safety are clear
and well documented, is one step we can
all take to extend the period of utility of
the fluoroquinolone class.
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